Viral infections and renal transplantation
Abstract
В настоящее время известно несколько вирусов гепатита (A, B, C, D, E, G и др.), и число открытых вирусов продолжает расти. Однако в клинической трансплантологии наибольшее значение имеют 2 вируса: вирус гепатита B (HBV) и вирус гепатита C (HCV). В нашей стране распространенность вирусных гепатитов среди пациентов диализных центров и реципиентов почечного трансплантата достаточно высока [2, 3].
About the Authors
E. I. Prokopenko
МОНИКИ им. М.Ф. Владимирского, г. Москва
Russian Federation
Russian Federation
N. E. Boudnikova
МОНИКИ им. М.Ф. Владимирского, г. Москва
Russian Federation
Russian Federation
References
1. Ватазин А.В., Молочков В.А., Казанцева И.А. и др. Саркома Капоши у больных после трансплантации почки (опыт одного центра). Нефрология и диализ 2001; 1 (2): 86-89.
2. Зубкин М.Л., Селькова Е.П., Стаханова В.М. и др. Гепатит B в центрах гемодиализа Москвы: клинико-эпидемиологическая характеристика. Нефрология и диализ 2001; 3 (4): 442-447.
3. Иванова И.П. Трансплантация почки и гепатиты: особенности диагностики, лечения и профилактики у больных хронической почечной недостаточностью: Автореф. дисс. … канд. мед. наук. 1998; 32.
4. Майер К.-П. Гепатит и последствия гепатита. М.: Гэотар Медицина 1999: 423.
5. Суханов А.В. Полиомавирусная нефропатия трансплантата. Нефрология и диализ 2001; 3 (4): 411-413.
6. Шмарина Н.В., Тарабарко Н.В., Ржевская О.Н. и др. Оценка влияния рекомбинантного интерлейкина-1-бета у больных с терминальной стадией ХПН в лечении вирусных гепатитов B и C до трансплантации почки на течение раннего послеоперационного периода. Вестник трансплантологии и искусственных органов. 2003; 1: 24-27.
7. Ahsan N., Holman M.J., Gocke C.D. et al. Pure red cell aplasia due to parvovirus B19 infection in solid organ transplantation. Clin Transplant 1997; 11 (4): 265-270.
8. Ali M., Light G., Barhyte D. et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation 1998; 66: 1694-1697.
9. Baid S., Pascual M., Williams W.W. Jr. et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10 (1): 146-153.
10. Batty D.S. Jr., Swanson S.J., Kirk A.D. et al. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001 Jul; 1 (2): 179-184.
11. Berthoux P., Dejean C., Cecillon S. et al. High prevalence of hepatitis G virus (HGV) infection in renal transplantation. Nephrol Dial Transplant 1998; 13 (11): 2909-2013.
12. Berthoux P., Laurent B., Cecillon S., Berthoux F. Membranoproliferative glomerulonephritis with subendothelial deposits (type 1) associated with hepatitis G virus infection in a renal transplant recipient. Am J Nephrol 1999; 19 (4): 513-518.
13. Bertoux F.C., Broyet C., Alamartine E. et al. HBs antigen positive organ donors and anti-HCV positive organ donors in renal transplantation. In: Touraine J.L. et al., eds. Transplantation and Clinical Immunology XXIII. Elsevier Science Publishers BV: 1991.
14. Besisik F., Sever M.S., Dincer D. et al. Serial measurements of serum transaminases in renal transplant recipients with chronic hepatitis C: do they reflect disease severity? Clin Transplant 2000; 14 (6): 529-532.
15. Breitenfeldt M.K., Rasenack J., Berthold H. et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16 (2): 130-136.
16. Campistol J.M., Esforzado N., Andres A. et al. Problematica y resultados del transplante renal con donnates HBsAg o VHC positivos. Nefrologia 1998; 18: 78-81.
17. Campistol J.M., Esforzado N., Andres A. et al. Resultados del transplante renal utilizando rinones de donantes hepatitis C positivos y hepatitis B positiva. Nefrologia 1998; 18: 60-64.
18. Choi S.H., Chang S.P., Won J.C. et al. A case of persistent anemia in a renal transplant recipient: association with parvovirus B19 infection. Scand J Infect Dis 2002; 34 (1): 71-75.
19. Cruzado J.M., Carrera M., Torras J., Grinyo J.M. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001; 1 (2): 171-178.
20. Dalekos G.N., Zervou E., Elisaf M. et al. Antibodies to hepatitis E virus among several populations in Greece: increased prevalence in an hemodialysis unit. Transfusion 1998; 38 (6): 589-595.
21. De Filippi F., Lampertico P., Soffredini R. et al. High prevalence, low pathogenicity of hepatitis G virus in kidney transplant recipients. Dig Liver Dis 2001; 33 (6): 477-479.
22. Delladetsima J.K., Makris F., Psichogiou M. et al. Cholestatic syndrome with bile duct damage and loss in renal transplant recipients with HCV infection. Liver 2001; 2; 1 (2): 81-88.
23. Diamantis I., Vafiadis I., Voskaridou E. et al. Genotype distribution of hepatitis C virus infection in Greece: correlation with different risk factors and response to interferon therapy. Eur J Gastroenterol Hepatol 1998; 10 (1): 75-79.
24. Fishman J.A., Rubin R.H. Medical progress: Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751.
25. Fontaine H., Thiers V., Chretien Y. et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69 (10): 2090-2094.
26. Fornarion S., Pol S., Legendre C. et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62: 297-299.
27. Gentil M.A., Luna E., Rodriguez-Algarra G. et al. Incidence of diabetes mellitus requiring insulin treatment after renal transplantation in patients with hepatitis C. Nephrol Dial Transplant 2002; 17 (5): 887-891.
28. Goffin E., Pirson Y., van Ypersele de Strihou C. Implications of chronic hepatitis B or hepatitis C infection for renal transplant candidates. Nephrol Dial Transplant 1995; 10: 88-92.
29. Hanafusa T., Ichikawa Y., Kishikawa H. et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-476.
30. Hanrotel C., Toupance O., Lavaud S. et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001; 88 (2): 120-126.
31. Huraib S., Iqbal A., Tanimu D., Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001; 21 (6): 435-440.
32. Ichikawa Y., Kyo M., Hanafusa T. et al. A 20-year case study of a kidney transplant recipient with chronic active hepatitis C: clinical course and successful treatment for late acute rejection induced by interferon therapy. Transplantation 1998; 65 (1): 134-138.
33. Isaacson A.H., Bhardwaj B., Qian K. et al. Hepatitis G virus infection in renal transplant recipients. J Viral Hepat 1999; 6 (2): 151-160.
34. Izopet J., Rostaing L., Sandres K. et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181 (3): 852-858.
35. Jeong H.J., Choi K.H., Chon C.Y. et al. Membranoproliferative glomerulonephritis associated with HCV infection in native kidneys and renal allograft. J Korean Med Sci 1998; 13 (6): 670-675.
36. Jung Y.O., Lee Y.S., Yang W.S. et al. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplantation 1998; 66 (6): 733-737.
37. Kasiske B., Ramos E.L., Gaston R.S. et al. The evaluation of renal transplant candidates: clinical practice guidelines. J Am Soc Nephrol 1995; 6: 1-34.
38. Kletzmayr J., Watschinger B., Muller C. et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000; 70 (9): 1404-1407.
39. Knoll G.A., Tankersley M.R., Lee J.Y. et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kid Dis 1997; 29: 608-614.
40. Lamproye A., Delwaide J., Vaira D. et al. Prevalence of hepatitis G virus in a haemodialysis unit. Acta Gastroenterol Belg 1999; 62 (1): 13-15.
41. Lee H.K., Yoon G.S., Min K.S. et al. Fibrosing cholestatic hepatitis: a report of three cases. J Korean Med Sci 2000; 15 (1): 111-114.
42. Lee P.C., Hung C.J., Lin Y.J. et al. A role for chronic parvovirus B19 infection in liver dysfunction in renal transplant recipients? Transplantation 2002; 73 (10): 1635-1639.
43. Lee W.C., Wu M.J., Cheng C.H. et al. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38 (5): 1074-1081.
44. Lui S.L., Luk W.K., Cheung C.Y. et al. Nosocomial outbreak of parvovirus B19 infection in a renal transplant unit. Transplantation 2001; 71 (1): 59-64.
45. Martin P., Carter D., Fabrizi F. et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000; 69 (7): 1479-1484.
46. Mathurin P., Mouquet C., Poynard T. et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29 (1): 257-263.
47. Molmenti E.P., Jain A.B., Shapiro R. et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. Transplantation 2001; 71 (2): 267-271.
48. Morales J., Campistol J., Castellano G. et al. Transplantations of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995; 47: 236-240.
49. Morales J.M., Campistol J.M., Andres A., Rodicio J.L. Hepatitis C virus and renal transplantation. Curr Opin Nephrol Hypertens 1998; 7: 177-183.
50. Morales J.M., Pascual-Capdevila J., Campistol J.M. et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997; 63 (11): 1634-1639.
51. Moudgil A., Shidban H., Nast C.C. et al. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 1997; 64 (12): 1847-1850.
52. Munos de Bastillo E., Ibarrola C., Andres A. et al. Hepatitis-B-related fibrosing cholestatic hepatitis after renal transplantation with acute renal graft failure following interferon-alfa therapy. Nephrol Dial Transplant 1998; 13: 1574-1576.
53. Munoz de Bustillo E., Ibarrola C., Colina F. et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant patients. J Am Soc Neplirol 1998; 9: 1109-1113.
54. Murer L., Zacchello G., Bianchi D. et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol 2000; 11 (6): 1132-1137.
55. Ok E., Unsal A., Celik A. et al. Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients. Nephrol Dial Transplant 1998; 13 (12): 3103-3107.
56. Pamidi S., Friedman K., Kampalath B. et al. Human parvovirus B19 infection presenting as persistent anemia in renal transplant recipients. Transplantation 2000; 69 (12): 2666-2269.
57. Park S.K., Yang W.S., Lee Y.S. et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001; 16 (11): 2222-2228.
58. Pereira B.J., Wright T.L., Schmid C.H., Levey A.S. A controlled study of hepatitis C transmission by organ transplantation. Lancet 1995; 345: 484-487.
59. Peters M.G., Singer G., Howard T. et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68 (12): 1912-1914.
60. Pol S., Debure A., Degott C. et al. Chronic hepatitis in kidney allograft recipients. Lancet 1990; 335: 878-880.
61. Pol S., Romeo R., Zins B. et al. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. Kidney Int 1993; 44: 1097-1100.
62. Post A.B., Hricik D.E., Sterling R.K. et al. Resolution of hepatitis B viremia in a renal transplant recipient treated with alpha-2b interferon. Nephron 1998; 79 (4): 469-471.
63. Preikschat P., Gunther S., Reinhold S. et al. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 2002; 35 (2): 466-477.
64. Puchhammer-Stockl E., Mandl C.W., Kletzmayr J. et al. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis 2000; 181 (6): 2063-2066.
65. Rao K.V., Anderson W.R., Kasiske B.L., Dahl D.C. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993; 94: 241-250.
66. Rao K.V., Ma J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. Transplantation 1996; 62: 1765-1769.
67. Rostaing L., Izopet J., Arnaud C. et al. Long-term impact of superinfection by hepatitis G virus in hepatitis C virus-positive renal transplant patients. Transplantation 1999; 67 (4): 556-560.
68. Rostaing L., Izopet J., Baron E. et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431.
69. Rostaing L., Izopet J., Cisterne J.M. et al. Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: correlation with clinicopathological features. Transplantation 1998; 65 (7): 930-936.
70. Rostaing L., Izopet J., Sandres K. et al. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000; 69 (5): 991-994.
71. Rostaing L., Modesto A., Baron E. et al. Acute renal failure in kidney transplant patients treated with interferon alfa 2b for chronic hepatitis C. Nephron 1996; 74: 512-516.
72. Santos F.R., Haiashi A.R., Araujo M.R. et al. Lamivudine therapy for hepatitis B in renal transplantation. Braz J Med Biol Res 2002; 35 (2): 199-203.
73. Stark K., Meyer C.G., Tacke M. Hepatitis G virus RNA and hepatitis G virus antibodies in renal transplant recipients: prevalence and risk factors. Transplantation 1997; 64 (4): 608-612.
74. Tang S., Ho S.K., Moniri K. et al. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant. Transplantation 2002; 73 (1): 148-151.
75. Van Duijnhoven E.M., Christiaans M.H., Boots J.M. et al. A late episode of post-transplant diabetes mellitus during active hepatitis C infection in a renal allograft recipient using tacrolimus. Am J Kidney Dis 2002; 40 (1): 195-201.
76. Vosnides G.G. Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843-861.
77. Wong T.Y., Chan P.K., Leung C.B. et al. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am J Kidney Dis 1999; 34 (6): 1132-1136.
78. Yokosuka O., Ikeuchi T., Kanda T. et al. The prevalence of TT virus infection in renal transplant recipients in Brazil. Transplantation 2000; 70 (8): 1194-1197.
79. Zylberberg H., Carnot F., Mamzer M.F. et al. Hepatitis C virus related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997; 63: 158-160.
80. Zylberberg H., Nalpas B., Carnot F. et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17 (1): 129-133.
Review
For citations:
Prokopenko E.I., Boudnikova N.E. Viral infections and renal transplantation. Nephrology and Dialysis. 2003;5(3):200-206. (In Russ.)
Views:
6
Email this article 